Pharmaceuticals

Ligand Pharmac-B

Ligand Pharmaceuticals Reports Q1 2026 Earnings

Ligand Pharmaceuticals Reports Q1 2026 Earnings and Announces Acquisition of XOMA

Ligand Pharmac-B released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual revenue USD 51.72 M (forecast USD 58.86 M), actual EPS USD -0.6711 (forecast USD 0.9783)

Ligand Pharmaceuticals Announces Acquisition Plan for XOMA Royalty Corporation

Ligand Pharmac-B to release FY2026 Q1 earnings on May 7 Pre-Market EST, forecast revenue USD 58.86 M, EPS USD 1.048

Ligand Pharmaceuticals to Acquire Xoma for Nearly $740 Million

Assetmark Inc. Significantly Increased Holdings in Ligand Pharmaceuticals

US Bank Gives Ligand Pharmaceuticals a 'Buy' Rating

Ligand Pharmac-B released FY2025 Q4 earnings on February 26 Pre-Market EST, actual revenue USD 59.67 M (forecast USD 55.59 M), actual EPS USD 2.12 (forecast USD 0.8075)

Ligand Pharmac-B released FY2025 earnings on February 26 Pre-Market (EST), actual revenue USD 268.09 M (forecast USD 264.01 M), actual EPS USD 6.13 (forecast USD 4.429)

Ligand Pharmac-B to Release FY2025 Q4 Earnings on February 26, Pre-Market EST; Forecast Revenue USD 55.59 M, EPS USD 0.8038

Ligand Pharmaceuticals Inc. CEO and CFO to Attend Oppenheimer's 36th Annual Healthcare Life Sciences Conference

Ligand's CFO Sells Company Common Stock

Benchmark Co. and H.C. Wainwright Maintain Buy Ratings for Ligand Pharma

Ligand Pharmac-B released FY2025 9 Months earnings on November 6 Pre-Market (EST), actual revenue USD 208.42 M, actual EPS USD 3.7079

Ligand Pharmac-B released FY2025 Q3 earnings on November 6 Pre-Market (EST), actual revenue USD 115.46 M (forecast USD 58.05 M), actual EPS USD 5.68 (forecast USD 1.0466)

Ligand Pharmac-B to Release FY2025 Q3 Earnings on November 6, Pre-Market EST; Forecast Revenue USD 58.71 M, EPS USD 1.0657

Ligand Pharmaceuticals Director John W. Kozarich Sells Common Stock

Oppenheimer Raises Ligand's Price Target to $190

Ligand Pharmaceuticals Reaches 52-Week High, HC Wainwright Raises Price Target

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Micware

BiomX

Vida Global

MicroAlgo

MetaVia

Quantum Cyber NV

LGND

XOMA

Ligand Pharmaceuticals has amended its merger agreement with XOMA Royalty to include XOMA Royalty Holdings as a party. This amendment facilitates a reorganization under which Ligand's Merger Sub will merge with HoldCo, which will become a wholly owned subsidiary of Ligand. The change aims to streamline the acquisition process of XOMA Royalty.

TradingView

XOMA Royalty

XOMA Corp Pref Share 8.625 Perp 12/15/21

XOMA Pref Share XOMAO 8.375 Perp 04/15/22 B

Ligand Pharmaceuticals Amends XOMA Royalty Merger Agreement to Add Holding Company

Earnings Watch

Ligand Pharmac-B | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 51.72 M

Ligand Pharmaceuticals (LGND) reported Q1 2026 revenue of $51.7 million with a basic EPS loss of $0.67, contrasting with a net loss of $13.3 million. Despite a trailing twelve-month EPS of $7.87 and net income of $153.6 million, the company faces earnings volatility. The stock trades at a P/E of 27.4x, above the industry average of 16.7x, with a DCF fair value estimate of $377.68. While forecasts suggest 16% annual earnings growth, the five-year earnings trend shows a decline of about 2.5% per year, creating tension between past performance and future expectations.

Simplywall

Ligand Pharmaceuticals (LGND) Returns To Trailing Profitability Challenging Cautious Earnings Narratives

Ligand Pharmaceuticals (NASDAQ:LGND) shares gapped down to $205.00 after reporting disappointing earnings, missing EPS estimates of $1.84 with $1.63. Revenue was $51.72 million, below the expected $59.10 million, despite a 14.1% year-over-year increase. Analysts have mixed ratings, with a consensus of "Moderate Buy" and an average target price of $256.29. Insider trading activity included sales by directors, and institutional investors hold 91.28% of the stock. The stock last traded at $211.97 with a volume of 88,559 shares.

Market Beat

Ligand Pharmaceuticals (NASDAQ:LGND) Shares Gap Down  After Earnings Miss

UTHR

United Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.

benzinga_article

United Therap

Ligand Pharmac-B | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 51.72 M

RMAX

KALV

REAX

Halper Sadeh LLC is investigating XOMA, RMAX, and KALV for potential violations of federal securities laws and breaches of fiduciary duties to shareholders. The firm is concerned that insiders may benefit financially from proposed transactions that could limit competing offers. Shareholders are encouraged to contact the firm for their rights and options regarding XOMA's sale to Ligand Pharmaceuticals, RMAX's sale to The Real Brokerage, and KALV's sale to Chiesi Group. Halper Sadeh LLC aims to seek increased consideration and other benefits for shareholders.

Ligand Pharmac-B(LGND.US)

Ligand Pharmaceuticals Amends XOMA Royalty Merger Agreement to Add Holding Company

Ligand Pharmac-B | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 51.72 M

Ligand Pharmaceuticals (LGND) Returns To Trailing Profitability Challenging Cautious Earnings Narratives

Ligand Pharmaceuticals (NASDAQ:LGND) Shares Gap Down After Earnings Miss

United Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.

Ligand Pharmac-B | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 51.72 M

14:55 ETAre XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?